This puts forth the idea that whereas GR activation has a detrimental effect on AR signaling-deficient prostate cancer, it can also inhibit the progression of prostate cancers from androgen dependence to hormone resistance as long as AR is still functionally active. This evidence concerns the gene NR3C1 and prostate carcinoma.